Editas Medicine Announces $117 Million Public Offering of Common Stock and Warrants

On May 26, 2026, Editas Medicine, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC for a public offering of 55,555,556 shares of common stock and accompanying common stock warrants. Each share and warrant is being sold at a combined public offering price of $2.25, with the underwriters purchasing them at $2.1150. The company expects net proceeds of approximately $117.0 million, which could increase by $192.5 million if all warrants are exercised in cash at the $3.50 exercise price. The common stock warrants are immediately exercisable and will expire on the earlier of three years from issuance or 30 days following the public announcement of Phase 1 clinical data for EDIT-401 showing at least three patients with >80% LDL-cholesterol reduction. Editas estimates that the offering proceeds, combined with existing cash as of March 31, 2026, will extend its cash runway into the second half of 2028. The offering is expected to close around May 27, 2026.